Bajaj Healthcare Ltd. is a company established in 1993, services various Pharmaceuticals, Nutraceutical and Food industries globally with a spirit of scrupulousness.Bajaj Healthcare Ltd. have metamorphosed into specialty company and focused on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries. Recently, Bajaj Healthcare Limited (BHL)announced the launch of “Posaconazole API” used in treating Mucormycosis (Black Fungus) infection in Covid-19 patients. Bajaj Healthcare is a leading manufacturer of APIs, Intermediates and Formulations.
BHL has received approval from FDA Gandhi Nagar, Gujarat (India), to manufacture and market “Posaconazole API” as approved medication for treating Mucormycosis in India and it will commence its commercial production from the first week of June 2021. Black fungus is a deadly fungal infection and has triggered a new health challenge in the country. More than 11,000 cases of black fungal infection have been reported from different parts, forcing state governments to declare it an epidemic. Posaconazole is a triazole antifungal agent indicated for treating Mucormycosis patients popularly known as Black Fungus in post-Covid complications. Commenting on the launch, Anil Jain, Joint Managing Director, Bajaj Healthcare said, “We are pleased to add Posaconazole API to our growing product portfolios. The second wave of coronavirus is more aggressive and bigger in number than the first. We hope the availability of an effective treatment such as Posaconazole will considerably ease the pressure and offer patients much-needed and timely therapy option.” The commercial production of the API is expected to begin in the first week of June and it will be marketed in the domestic as well as overseas market. It will be available as a prescription-based medication, with recommended doses.
The fungal infection that has emerged during the second wave has been widely linked with excessive usage of steroids and uncontrolled diabetes in coronavirus positive patients. Bajaj Healthcare is a leading manufacturer of APIs, intermediates and formulations. It specializes in manufacturing of of amino acids, intermediates, API, formulations & nutraceuticals. The company’s net profit surged to Rs 326.1% to Rs 26.42 crore on a 79.6% rise in net sales to Rs 178.33 crore in Q3 FY21 over Q3 FY20.
